Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Bakkt (BKKT) Research & Development (2021 - 2026)

Bakkt's Research & Development history spans 6 years, with the latest figure at $1.8 million for Q1 2026.

  • Quarterly Research & Development fell 8.64% to $1.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.7 million through Mar 2026, down 12.49% year-over-year, with the annual reading at $7.3 million for FY2025, 22.89% down from the prior year.
  • Research & Development came in at $1.8 million for Q1 2026, down from $1.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.9 million in Q1 2024 to a low of -$3.2 million in Q4 2023.
  • The 5-year median for Research & Development is $3.7 million (2024), against an average of $3.2 million.
  • Year-over-year, Research & Development tumbled 171.47% in 2023 and then soared 168.69% in 2024.
  • Bakkt's Research & Development stood at $4.4 million in 2022, then plummeted by 171.47% to -$3.2 million in 2023, then soared by 168.69% to $2.2 million in 2024, then dropped by 17.24% to $1.8 million in 2025, then fell by 0.5% to $1.8 million in 2026.
  • Per Business Quant, the three most recent readings for BKKT's Research & Development are $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $2.2 million (Q3 2025).